A Smart and Portable Dialysis—A Lifechanging Solution for Millions of People with Kidney Failure Requiring Dialysis
liberDi has developed a portable, automatic dialysis system which enables people with kidney failure to receive treatment from anywhere, anytime. liberDi's cutting-edge technology significantly improves patients' quality of life, who up until now were forced to travel to dialysis centers several times a week and undergo tedious treatments of 3-5 hours per treatment. With an innovative, patent protected technology, liberDi dramatically improves the quality of at-home dialysis treatments being designed to reduce treatment related infections and helping maintain patients' normal daily routines; thus, encouraging more patients to opt for treatments outside of dialysis centers.
The Digital Health Revolution in Nephrology – A Cloud-Based Digital Dialysis Center
With an innovative, intelligent computerized platform, liberDi created a digital dialysis clinic enabling healthcare practitioners and dialysis patients to provide and receive personalized treatment from anywhere in the world, without having to go to a dialysis clinic. The information is stored in a secured cloud-based platform, analyzed to generate customized alerts and insights, and automatically distributed to clinics for further monitoring by nurses and doctors.
A Successful Business Model: Financial Benefits for Patients, Caregivers, Dialysis Organizations and Healthcare Systems
liberDi's Digital Dialysis Clinic will instigate a financial revolution in the dialysis treatment market, by saving substantial costs for healthcare providers and insurance companies worldwide. This model empowers caregivers to support a higher number of patients through a secure, monitored and automated platform. This model also enables patients maintain their professional routine due to the flexibility and reduction in treatment duration.
An Innovation Funded by the Technion's Research Foundation and Israel's Top Tech Incubators
liberDi was established in collaboration with the Technion Research and Development Foundation (TRDF) and Trendlines Medical incubator, which specializes in medical technology investments, alongside experienced angel investors, the Arbelon Holdings Ltd fund and Rimoni Industries, which focuses on med-tech management and investments.
The Israel Innovation Authority and the European Commission – Horizon 2020 Grants
The company has received R&D grants from the Israel Innovation Authority and won the prestigious Horizon 2020 European Funding for Research & Innovation from the European Commission, given to industry pioneers and companies displaying scientific excellence.
Successful Clinical Trials in Collaboration with "Clalit Health Services"
liberDi has completed successful clinical trials in collaboration with "Clalit Health Services", conducted in the HMO's hospitals in Israel. The device is currently in advanced stages for an FDA approval, which will allow the company to soon start large-scale commercial activities.
First Prize Winner in a Prestigious Med-Tech Start-Up Competition
liberDi is the first prize winner of the "100k MedTech Startup Contest" organized by the mHealth scientific journal, which covers innovative medical technologies and breakthroughs in the telemedicine field, and supported by Medimor and the Baruch Padeh Medical Center, Poria. The first prize also awarded the company substantial funds.
A Team made of the Best Engineers and Medical Specialists
liberDi was founded by a strong team of world-class scientists and engineers with extensive expertise in the field of nephrology. The company’s scientific advisory board is comprised of nephrologists and professors holding senior clinical and academic positions at international dialysis organizations and major hospitals in Israel and abroad.
Over 10% of the world's population suffers from chronic kidney disease, which can lead to kidney failure since the body fails to eliminate waste, toxins and water excess from the blood. In such cases, dialysis treatment is required to prolong patients' lives, in which the treatment replaces kidney function until a kidney transplant is possible.
Traditionally, dialysis is performed in specialized dialysis centers or at hospitals with dedicated dialysis departments. Patients must travel to the center three times a week to attend a 3 to 5 hours treatment session which is often accompanied by side effects such as fainting, fatigue, nausea, or vomiting. In fact, many patients feel that dialysis takes over their lives and gets in the way of conducting normal daily routines.
As opposed to hemodialysis (dialysis of the blood), which is performed in dialysis centers, peritoneal dialysis (PD), takes place in the peritoneum, can be performed at home, at a lower cost and with less side-effects. At-home dialysis can deliver a better patient experience and outlook regarding treatment. Thus, this treatment method improves patients' quality of life. However, only 12% of all dialysis patients opt for PD. Nowadays, peritoneal dialysis at home requires a sterile environment, as the main treatment risk is an abdominal infection. Furthermore, the treatment is usually comprised of cumbersome equipment, requires a lot of effort and time to prepare and operate, and does not include professional monitoring and management—making patients more prone to complications.
Additionally, the transition of clinical treatment and surveillance to digital interfaces and to patients' familiar home environment has become a trend in the past years, specifically following the COVID-19 pandemic—during which chronic patients were confined to their homes. The dialysis treatment market has not experienced any significant innovations in over 30 years, and is finally refusing to stay behind.
liberDi's innovation is a total gamechanger in the global dialysis market, with the Digital Dialysis Clinic that operates a portable dialysis device that can be used anywhere, anytime and an intelligent digital platform for patient management. The computerized system conducts continuous treatment monitoring by medical professionals; the user-friendly dialysis device reduces infections while empowering patients to persist with the treatment; together, this can improve dialysis patients' quality of life and quality of treatment. For the first time ever, patients can lead a full and active lifestyle, while simultaneously reducing costs for healthcare organizations and dialysis centers worldwide.
The Technology
liberDi's automatic and portable dialysis system allows more people to enjoy the benefits of peritoneal dialysis.
The Digital Dialysis Clinic is comprised of:
The cloud-based computerized platform connects patients with medical professionals that conduct ongoing monitoring of treatment progression to prevent complications. The digital monitoring portal sends real-time alerts to both patients and the medical team. It also syncs with different devices, such as blood pressure monitors and digital scales, so information can be efficiently transferred.
The portable dialysis device, the Intelligent Dialysis Assistant (IDA), performs peritoneal dialysis (in the peritoneum). As opposed to hemodialysis, which takes hours to complete, the entire PD process, from start to finish, takes approximately 20 minutes.
How it works –in 5 steps:
IDA's Infection-Control Technology
|
Biography
B.Sc. Mechanical Engineering - Technion - Israel Institute of Technology; M.Sc. Management - New York University -Tandon School of Engineering. 20+ years’ experience R&D, international business, operations; former executive positions with PV Nanocell, D Medical Industries, MCS, Mentorwave, Power Paper. Hezkiah is a management executive in medical device and biotechnology ventures. He has strong background in technology, as well as in management, creates a perfect combination to lead entrepreneurial technological ventures Mr. Tsoory recently co-founded liberDi, a company committed to providing a breakthrough solution with the potential to dramatically improve the lives of people with end-stage renal disease (ESRD). liberDi has developed an automated peritoneal dialysis (PD) system that is small and portable and addresses the adverse side-effects associated with other currently available treatments. With proven track record in • Forming international strategic collaborations • Strategic planning and execution • Bringing new products to market • Executing multidisciplinary R&D projects • Fundraising
|
|
Biography
Head, Department of Nephrology and Hypertension, Carmel Medical Center. President, Israeli Society of Nephrology and Hypertension. 20+ years’ experience as specialist in nephrology and hypertension Dr. Frajewicki started his training in Internal Medicine in Buenos Aires, Argentina. He completed his medical formation in the Department of Nephrology and Hypertension at the Carmel Medical Center affiliated to the Technion Institute of Technology in Haifa. He currently is the Head of the Department. His main interests are focusing on clinical and basic research on dialysis, both hemo and peritoneal dialysis. By now Dr Frajewicki is the President of the Israeli Society of Nephrology and Hypertension, dealing with issues of public health in Israel.
|
|
Biography
Head of the Institute of Nephrology, Rabin Medical Center (Beilinson & Hasharon hospitals), Petah Tikva, Israel; 30 years clinical and research experience in the field of Nephrology in general, and in peritoneal dialysis in particular Prof Avry Chagnac is an internationally recognized researcher in nephrology. He previously served as head of the Department of Nephrology at Rabin Medical Center and Tel Aviv University. He has extensive clinical and research experience in the field of nephrology in general, and in peritoneal dialysis in particular. He has authored or co-authored more than 100 publications. He served as chairman of the Israeli Peritoneal Dialysis Committee. In 2018 he was awarded a prize by The Israeli Society of Nephrology for his contribution to research in nephrology.
|
|
Biography
Head of peritoneal dialysis unit, Imperial College Kidney and Transplant Centre, Hammersmith Hospital, London, UK. Co-organiser of UK PD Academy. Extensive research and education related to outcomes of older patients on dialysis. Chair of the guidelines committee, International Society of Peritoneal Dialysis A clinical nephrologist with an international reputation in peritoneal dialysis (PD). She is currently chair of the clinical guideline committee for the International Society of Peritoneal Dialysis. She is the head of the PD programme at Hammersmith Hospital, London, UK (currently 150 patients) and is an honorary professor of renal medicine at Imperial College London. She has been the lead investigator of key multicentre studies related to PD including the European APD Outcome Study (EAPOS). She initiated the development of assisted PD in the UK. She has been on the organising faculty of the UK PD Academy since its initiation in 2000, published more than 150 papers and published several books, including the Oxford Handbook of Dialysis (now in 4th edition).
|
|
Biography
Served for almost 3 decades on the board of B. Braun Group of companies and as CEO of B. Braun North America. He is currently Executive Advisor to Water Street Healthcare Partners LLP in Chicago. Mr. Neubauer has advanced meaningful change and innovation in the healthcareindustry as a long time Board Member of AdvaMed and other healthcare organizations, for which he has recieved numerous awards.
|
|
Biography
a Certified Public Accountant, with over 20 years of experience in CFO and financial advisory positions in technology and med-tech sectors. Holds a L.L.B. and B.B. degrees in business administration.
|